Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hendrik Otto

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Expert Opinion on Biological Therapy|October 7, 2022
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringeNemanja Damjanov, Nana Kirvalidze, Nana Kurashvili, et al.
Expert Opinion on Investigational Drugs|May 22, 2023
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adultsChristopher Wynne, Paul Hamilton, Kristi McLendon, et al.
Expert Opinion on Biological Therapy|June 13, 2025
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degenerationHansjürgen Agostini, Kristine Baumane, Vilma Jūratė Balčiūnienė, et al.
Expert Opinion on Biological Therapy|July 23, 2025
A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosisMamuka Lortkipanidze, Tobie de Villiers, Grzegorz Kania, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 17, 2021
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III StudySteven R Feldman, Nataliya Reznichenko, Grazyna Pulka, et al.
Cell|January 21, 2014
Inefficient SRP interaction with a nascent chain triggers a mRNA quality control pathwayAndrey L Karamyshev, Anna E Patrick, Zemfira N Karamysheva, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Expert Opinion on Biological Therapy|October 7, 2022
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringeNemanja Damjanov, Nana Kirvalidze, Nana Kurashvili, et al.
Expert Opinion on Investigational Drugs|May 22, 2023
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adultsChristopher Wynne, Paul Hamilton, Kristi McLendon, et al.
Expert Opinion on Biological Therapy|June 13, 2025
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degenerationHansjürgen Agostini, Kristine Baumane, Vilma Jūratė Balčiūnienė, et al.
Expert Opinion on Biological Therapy|July 23, 2025
A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosisMamuka Lortkipanidze, Tobie de Villiers, Grzegorz Kania, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 17, 2021
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III StudySteven R Feldman, Nataliya Reznichenko, Grazyna Pulka, et al.
Cell|January 21, 2014
Inefficient SRP interaction with a nascent chain triggers a mRNA quality control pathwayAndrey L Karamyshev, Anna E Patrick, Zemfira N Karamysheva, et al.
Pageof 2